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Available online 6 September 2016Dynamic range limitations are challenging to proteomics, particularly in clinical samples. Afﬁnity proteomics par-
tially overcomes this, yet suffers from dependence on reagent quality. SOMAscan, an aptamer-based platform for
over 1000 proteins, avoids that issue using nucleic acid binders. Targets include low expressed proteins not easily
accessible by other approaches. Herewe report on the potential of SOMAscan for the study of differently sourced
mesenchymal stem cells (MSC) in comparison to LC-MS/MS and RNA sequencing. While targeting fewer
analytes, SOMAscan displays high precision and dynamic range coverage, allowing quantiﬁcation of proteins
not measured by the other platforms. Expression between cell types (ESC and MSC) was compared across tech-
niques and uncovered the expected large differences. Sourcing was investigated by comparing subtypes: bone
marrow-derived, standard in clinical studies, and ESC-derivedMSC, thought to hold similar potential but devoid
of inter-donor variability and proliferating faster in vitro. We conﬁrmed subtype-equivalency, as well as vesicle
and extracellular matrix related processes in MSC. In contrast, the proliferative nature of ESC was captured less
by SOMAscan,wherenuclear proteins are underrepresented. The complementary of SOMAscan allowed the com-
prehensive exploration of CDmarkers and signalingmolecules, not readily accessible otherwise and offering un-
precedented potential in subtype characterization.
Signiﬁcance:Mesenchymal stem cells (MSC) represent promising stem cell-derived therapeutics as indicated by
their application in N500 clinical trials currently registered with the NIH. Tissue-derived MSC require invasive
harvesting and imply donor-to-donor differences, towhich embryonic stem cell (ESC)-derivedMSCmay provide
an alternative and thuswarrant thorough characterization. In continuation of our previous studywherewe com-
pared in depth embryonic stem cells (ESC) and MSC from two sources (bone marrow and ESC-derived), we in-
cluded the aptamer-based SOMAscan assay, complementing LC-MS/MS and RNA-seq data. Furthermore,
SOMAscan, a targeted proteomics platform developed for analyzing clinical samples, has been benchmarked
against established analytical platforms (LC-MS/MS and RNA-seq) using stem cell comparisons as a model.







Measuring protein expression level differences is crucial to the fun-
damental understanding of biological systems. Although the current, embryonic stem cell-derived
ved mesenchymal stem cells;









. This is an open access article underpreferred technique in quantitative proteomics remains liquid chroma-
tography coupled to mass spectrometry (LC-MS/MS), afﬁnity-based
techniques have recently gained in analytical power and consequently
popularity. The aptamer-based SOMAscan assay [1], a relatively recent
addition to the ﬁeld of targeted afﬁnity proteomics, allows for the simul-
taneous measurement and quantitation of 1095 proteins by 1129
unique SOMAmers (slow offrate modiﬁed aptamers; version 1.1 k).
The assay was designed for the analysis of clinical samples, character-
ized by high complexity and dynamic range. By using only a fewmicro-
liters of bio ﬂuid (70 μl of plasma or 20 μg of protein sample), and
allowing for high throughput measurements (upwards of 84 samples
per day in its robotic implementation) it is suitable for clinical studies
in the context of human genetic heterogeneity. According to themanu-
facturer, the dynamic range of the assay covers 8 orders of magnitude
and measures molecules with high sensitivity (median lower limit of
detection of 40 fM) and speciﬁcity superior to antibody-mediatedthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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human plasma [3]. Aptamers in this assay are short single stranded 40
base DNAs including non-natural nucleotides. In marked difference to
afﬁnity proteomics using antibody arrays, this implies that they are eas-
ily produced synthetically and in bulk. Additionally they can be quanti-
ﬁed through hybridization to complementary probes on a chip or slide,
utilizing the mature technology suite stemming from RNA arrays. Sam-
ple preparation is simple, consisting only of dilution and not requiring
any pre-processing steps. Overall, the SOMAscan assay (SOMA) targets
a limited subset of the proteome but overcomes classical dynamic
range limitations. Although it was developed speciﬁcally for high
throughput screening of clinical samples in biological matrices such as
serum, plasma and cerebrospinal ﬂuid, it has recently been applied as
well to cell extracts [4] and exosomes [5].
Here we used samples from human embryonic and mesenchymal
stem cell populations to assess the complementarity of SOMAscan to
more commonly used techniques: liquid chromatography coupled to
high resolution mass spectrometry (LC-MS/MS) and next generation
RNA sequencing (RNA-seq). The inclusion of different stem cell model
systems allowed to probe both massive (ESC vs MSC) and subtle differ-
ences in protein expression (ESC-derived MSC vs bone marrow-derived
MSC) and thus characterize the SOMAscan performances for both cases.
In addition to the juxtaposition of the targeted proteomics assay to
mass spectrometry-based proteomics and RNA-seq, we aim to provide
complementary data on MSC to our previous report [6], particularly in
terms of CD markers and quantitative proteomic cell type signature.
This aim is particularly relevant for the latter cell type as, due to their
reduced risk in tumor formation, ease of access from adult tissues,
allogenicity and in vitro differentiationpotential into cells of themesoder-
mal lineages (osteocytes, chondrocytes and adipocytes [7,8]), MSCs are of
great interest in cell-based therapies. Functionally,MSC are immunomod-
ulatory and support tissue regeneration through paracrine activity by se-
creted molecules or extracellular vesicles rather than differentiation into
cells of the injured tissue [9]. Given their paracrine activity, we expected
the aptamer-based targeted proteomics platformwith its focus on secret-
ed proteins to be advantageous in the analysis of MSC, particularly as
those targets remain challenging for exploratory techniques.
2. Experimental procedures
2.1. Cell culture and SILAC labeling of embryonic stem cells (ESC) and mes-
enchymal stem cells (ESC-MSC, BM-MSC)
ESC-derivedMSCswere obtained from three independent differenti-
ation experiments using the previously reported protocol and have
been phenotyped to show classic MSC behavior [10].
Bone marrow-derived mesenchymal stem cells were purchased
with their mesenchymal characteristics veriﬁed. Details of the BM-
MSC donors were as follows: 40y/m (StemCell, MSC-001F,
lot#BM2893), 39y/m (Lonza, PT2505, lot#1F3422), 27y/m (Lonza,
PT2505, lot#318,006), 20y/m (Lonza, PT2505, lot#8F3520).
Permission to use the human embryonic stem cell line (hESC) ES04
(WiCell institute) was obtained from the Cornell/Rockefeller/Sloan Ket-
tering tri-institutional ESC research oversight committee. Funding was
secured from nonfederal, US-external funding sources.
For mass spectrometry-based analysis, a triplex SILAC experimental
design with label swapping was employed as previously described [6].
For SOMAscan-based analysis and RNA sequencing, cells were grown
in standard conditions [6].
2.2. Sample preparation for the SOMAscan assay
Cells were harvested by dispase (ESC; WiCell institute) or trypsin
(ESC-MSC, BM-MSC). After PBS washes of the cell pellet, total protein
was extracted with the MEM-Per buffer (Thermo Fisher Scientiﬁc) sup-
plemented with protease inhibitors (Complete, EDTA-free, Roche).Protein concentration was determined by Bradford assay and adjusted
to 0.5 μg/μl. Total protein extracts of ESC, ESC-MSC and BM-MSC sam-
ples were sent to SomaLogic (Colorado, USA) as part of a fee for service
agreement and subjected to SOMAscan analysis according to standard
protocol [11].2.3. Sample preparation for mass spectrometry
Protein samples were prepared as described previously [6]. Brieﬂy,
proteins were extracted using the Nuclear Extract Kit (ActiveMotif) to
get cytosolic (CYT), nuclear (NUC) and chromatin-bound (CH) proteins.
After methanol-chloroform precipitation, samples were resuspended in
8 M urea buffer (6 M urea, 2 M thiourea, 30 mM HEPES, pH 8) and
digested with Lys-C for 3 h, followed by overnight trypsination after di-
lution to 2Murea. Peptideswere separated by in-solution isoelectric fo-
cusing into 12 fractions. After fractionation, peptides were desalted on
C18 STAGETips [12]. Per sample, 36 fractions (12× CYT, 12× NUC, 12×
CH) were measured by mass spectrometry.2.4. Mass spectrometry
Peptides were subsequently analyzed by liquid chromatography
(LC) using an EASY nLC-II system coupled to a Q Exactive mass spec-
trometer (MS) (Thermo Scientiﬁc, Bremen, Germany) as previously de-
scribed [6,13].
MS data was analyzed by MaxQuant suite of algorithms version
1.4.1.2 [14] using a Homo Sapiens database downloaded from
UniprotKB on the 27th of November 2013 and comprising 88,473 pro-
tein isoforms entries. MaxQuant analysis was performed on all com-
bined fractions and samples (36 MS runs per sample, grand total of
108 MS acquisitions) with an experimental design template reﬂecting
the triplicated triplex SILAC approach using previously reported search
parameter settings [6].2.5. Next generation RNA sequencing
Next generation RNA sequencing (RNA-seq) was performed as pre-
viously described [6]. Brieﬂy, total RNA was extracted with TRIZOL
followed by an on-column cleaning step. 100 ng of total RNA was con-
verted to cDNA using the Ovation RNA-seq System V2 (Nugen Technol-
ogies, San Carlos, CA). 2 μg of the ampliﬁed cDNA was sheared to 150–
200 bp size distribution by Adaptive Focused Acoustics using a Covaris
E220 instrument (Covaris, Woburn, MA). The sheared cDNA was end-
repaired to generate blunt ends, then ligated to Illumina compatible
adaptors with indexing tags, followed by 1× AMPure XP beads puriﬁca-
tion. The ﬁnal NGS libraries were quantiﬁed using Agilent Bioanalyzer
DNA Chip 1000 with 11 libraries per pool. Paired-end 100 bp deep se-
quencing was carried out on HiSeq 2500 (Illumina). RNA-seq analyses
were performed using a customized pipeline composed of TopHat [15]
Picard, (http://picard.sourceforge.net/index.shtml), Samtools [16] and
Cuffdiff [15].2.6. Statistical analysis
Proteomics data sets (SOMA, PROT) were analyzed with the empir-
ical Bayes moderated t-test implemented by the limma bioconductor
package [17] in the R environment [18]. p values were corrected for
multiple hypothesis testing using the Benjamini-Hochberg method
(FDR b0.05). Differential expression was calculated on normalized
log10 intensities (SOMAscan) or log2 ratios (nano LC-MS/MS). Differen-
tial expression for RNA sequencing data was performed with the
Cufﬂinks [15] package using the Cuffdiff function.
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Coefﬁcients of variations (CV) were calculated per feature across
replicates on logarithmized FPKM (fragments per kilobase of transcript
per million mapped reads) values for RNA sequencing, normalized pro-
tein intensities for PROT and relative ﬂuorescence units for SOMA. For
PROT, normalized protein intensities were obtained by aggregation of
peptide intensities and divided by the total protein intensity per repli-
cate. Distributions of CVs were reported per technique and cell type as
violin plots using R. Note that for CV of common geneproducts, only fea-
tures quantiﬁed in all three replicates per technique are reported.
For dynamic range coverage assessment, reference FPKM values
were obtained from ESC [19] (4 concatenated H1 replicates of the
BioProject PRJNA269573) and MSC (3 concatenated BM-MSC samples
of different donors, available at Galaxy, https://usegalaxy.org/u/cic19/
h/mesenchymal-stem-cells-rnaseq) [20] deep transcriptome data. The
reference sets were limited to annotated genes with FPKM values N0,
retaining only the ﬁrst isoform. For gene annotations consisting of mul-
tiple entries, only theﬁrst gene name in the groupwas used. Gene prod-
ucts identiﬁed in RNA, PROT and SOMA were mapped independently
onto the reference data sets, considering only products measured in
all three replicates. Resulting density distributions for the reference
and each technique were overlaid to visualize their respective dynamic
range coverage per cell type. Similarly, density plots for features com-
monly measured in all approaches have been plotted against their re-
spective reference per cell type (Fig. S1).
2.8. Bioinformatics
For classiﬁcation of proteins or genes, full id sets for each of the three
techniques (RNA, PROT, SOMA) were submitted to PANTHER [21]. PCA
was performed with the FactoMineR package v.1.29 [22] within the R
environment. For cell type comparisons, PCA for PROT was based on
non-normalized intensities derived from mass spectrometry. Enrich-
ment and pathway analyses were performed using functionality devel-
oped in-house within the R environment [18].
2.9. Data availability
Both RNA and PROT data derive from an earlier publication are ac-
cordingly publicly available [6].
3. Results
3.1. Comparative evaluation of the analytical techniques: replicate repro-
ducibility and dynamic range distribution
Evaluations of measurement repeatability and dynamic range were
considered due to their relative translatability across techniques. Coefﬁ-
cients of variation (CV, also RSD or relative standard deviation) for quan-
tiﬁed features were calculated per cell type (BM-MSC: BM, ESC-MSC: EM,
ESC: E) between biological replicates for all features measured per tech-
nique (Fig. 1A). To increase comparability, data sets were ﬁltered for fea-
tures commonlymeasured by all three techniques and quantiﬁed in each
replicate, which reduced their number to around 400 observations per
platform (Fig. 1B). Overall, coefﬁcients of variation (CV) appear compara-
ble across techniques with SOMAscan displaying the narrowest distribu-
tions with the lowestmedian for complete and subset datasets. However,Fig. 1.Measurement repeatability, dynamic range coverage andprotein groupdistribution acros
type for (A) all measured features or (B) commonly measured features. (C) Dynamic range c
measured by RNA, PROT and SOMA or commonly measured by all three techniques. (D) Quan
protein class distributions for each platform (RNA, PROT, SOMA) presented as counts and perc
the aptamer-based assay (SOMA) are highlighted by purple and grey arrows, respectively.SOMAscan's distributions of CV also show signiﬁcant kurtosis, particularly
apparent for BM-MSC, highlighting disparity in measurement precision
between targets. RNA and PROT both display wider CV distribution with
technique-based speciﬁcities: larger outlier population for RNA and larger
standard deviation and median values for PROT. The higher repeatability
observed for SOMA can be attributed to its detection speciﬁcity (aptamer
binding), unsurprisingly exceeding that of the non-targeted RNA and
PROT approaches. It is important to note that CV for PROT are based on
normalized protein intensities and not on logarithmized ratios (standard
for quantitative data analysis) due to the inapplicability of CV to ratio
analysis. The propagation of error inherent to a bottomup approach com-
binedwith the use of intensities over ratios directly accounts for the lower
performance of PROT reported here.
When considering the subset of commonly measured features, the
medians and standard deviations of the CV distributions remain similar
to those observed in the non-subset data sets, but a bimodal trend for
both RNA and PROT becomes apparent, presumably due to a subset of
commonly measured features having lower signal to noise values and
thus higher absolute variability. This is true in particular for BM-MSC
where sample heterogeneity is increased by donor-derived genetic
variability.
SomaLogic claims 8 orders of magnitude of dynamic range for their
aptamer based assay [2]. In the cell model used, evaluation of that claim
and quantiﬁcation of the obtainable dynamic range are non-trivial, as, to
the best of our knowledge, no global protein expression atlas exists for eu-
karyotes with the exception of yeast [23] or the more recent plasma pro-
teome database [24]. Therefore, the dynamic range of the techniques was
compared by mapping the identiﬁed gene products onto logarithmized
FPKM distributions from common reference transcriptomes of extensive
depth for ESC [19] and MSC [20] (Fig. 1C, 23,199 and 18,391 features, re-
spectively). For each analytical platform, distributions of the features
mapped to the reference dataset were overlaid per cell type. The overlap
between techniques and the reference set provides an estimation of their
intrinsic dynamic range for the cell model used. RNA and PROT behave
very similar in termsof dynamic range distribution,with aminor sensitiv-
ity advantage for RNA. The large depth achievedby PROTderives from the
extensive subcellular fractionation approach employed, narrowing the
gapwith RNA.However, only SOMAprovides coverage of lower abundant
features from the reference set. Additionally, the SOMA density distribu-
tion closely tracks that of the reference, indicating a lower dynamic
range bias than for the other approaches used. When considering com-
monly quantiﬁed features on all platforms, the resulting density distribu-
tions demonstrate thatmost of the overlap between techniques occurs for
highly abundant targets.
The feature numbers for the reference set for ESC and MSC as well as
the quantiﬁed features per platformmatching the reference are shown in
Fig. 1D. Due to the implied analyte ampliﬁcation, RNA is themost compre-
hensive techniquewith over 10,000 featuresmatching the reference, cor-
responding to N90% of its quantiﬁed features, followed by in-depth MS-
based proteomic proﬁling with 6800 features (also N90% of its reported
quantiﬁed features).With approximately 800 featuresmapped to the ref-
erence set, corresponding to about 70% of the probes, SOMA not only dis-
plays the lowest number of mapped features (expected due to the
comparatively low number of aptamers), but more importantly the low-
est overlap with the reference set. This may stem from SOMAscan quan-
tifying very low abundant proteins that often are at or below the limit
of detection of other platforms, including the in-depth RNA sequencing
data used as reference.s techniques. Violin plots of the coefﬁcients of variation distributions per technique and cell
overage of extensive ESC (left) and MSC (right) reference sets are reported for features
tiﬁed features from reference sets covered by each technique per cell type. (E) PANTHER
entages (left and right, respectively). Over- and underrepresented categories present for
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and cell signaling of ESC and MSC
3.2.1. Characterization of the subproteome targeted by SOMA
According to the PANTHER database [21], several protein classes are
overrepresented in SOMAwhen compared to RNA and PROT, including
signaling molecules (253), receptors (211), defense/immunity proteins
(146), proteases (120), cell adhesionmolecules (104), kinases (90) and
extracellular matrix (66). The high number of signaling molecules
stems from the fact that the assay was developed to target speciﬁcally
proteins present in bio ﬂuids such as plasma, and makes an excellent
tool for comprehensive pathway screening, with, among the top KEGG
pathways monitored by the assay: cytokine-cytokine receptor interac-
tion (173), MAPK signaling (78), JAK-STAT signaling (65), chemokine
signaling (58), cell adhesion (40), axon guidance (39), neurotrophin
signaling (38), ErbB signaling (36), Toll-like receptor signaling (32)
and TGFβ signaling (25). However, the corollary is the under-represen-
tation in the assay of organelle- or nucleus-related proteins, making di-
rect comparison to non-targeted techniques more limited when
considering cell line analysis (Fig. 1E).
3.2.2. Intra- and inter sample variability on SDEs
As expected, differences measured between embryonic and mesen-
chymal stem cells were massive, with 833 and 834 proteins
overexpressed in ESC-MSC and BM-MSC versus ESC, respectively. The
two MSC populations (ESC-MSC and BM-MSC) were very similar, with
only 119 modulated proteins reported between them (Fig. 2A, B, Fig.
S1 and Table S1). A correlationmatrix shows a high consistency of mea-
surements within each group and further demonstrates the differences
between ESC and MSC and the equivalence of the two MSC subpopula-
tions (Fig. 2C). Expectedly, ESC-MSCs derived from a single ES cell line
are more homogenous than donor-derived BM-MSC. Differences be-
tween ESC and MSC can be explained by the ﬁrst two components of a
principal component analysis (PCA) covering 98% of the observed vari-
ance (component 1: 94%, component 2: 4%). Only the third component
separates the two MSC types (Fig. 2D).
3.2.3. ESC features
391 SDE proteins were found up-regulated in ESC as compared to
MSC, among which the strongest was the only pluripotency-associated
transcription factor present in the assay: NANOG (31 fold) (Fig. S2B).
Applying a fold change cutoff of 2 to look for signiﬁcant changeswith
higher amplitude, 71 and 66 proteins were found up-regulated in ESC
when compared to ESC-MSC and BM-MSC, respectively, with 62 com-
monly elevated. Many of those (19) were nuclear proteins involved in
cell cycle such as checkpoint kinase 1 (CHEK1), aurora kinase B
(AURKB), cyclin B1 (CCNB1), cyclin-dependant kinase 2 (CDK2),
karyopherin alpha 2 (KPNA2), pescadillo ribosomal biogenesis factor 1
(PES1), and polo-like kinase 1 (PLK1), reﬂecting the comparatively
higher proliferation capacity of ESC. Immune response-related proteins
were also found to be highly enriched in ESC and the top KEGG path-
ways associated to up-regulated proteins in ESCwere cytokine-cytokine
receptor interaction, Ras signaling, NF-kappa B signaling and hemato-
poietic cell lineage (Fig. 2E, Fig. S3, DataSet S1). When comparing the
ESC proﬁle to both MSC subtypes, very similar results were observed,
conﬁrming close relatedness of MSCs despite the sourcing differences.
3.2.4. MSC features
351 SDE proteins were found up-regulated in both MSC subtypes as
compared to ESC; upon applying a fold change cut off of 2, that numberFig. 2. Differential expression analysis for SOMA. (A) Volcano plots for BM-MSC vs ESC (BM
differentially expressed proteins and the number of up-regulated proteins per cell type are re
(C) Pearson correlation matrix for all replicates. (D) PCA was performed on log10 intensities pl
Enrichment analysis based on GO biological process (GOBP), GO cellular compartment (GOCC
ESC comparisons are based on BM-E and EM-E intersections. Bar plots show the 20 most signidecreased to 157 up-regulated proteins, with 102 common between
ESC-MSC and BM-MSC. These were enriched for extracellular matrix
(ECM) and bone development terms, conforming to the mesodermal
differentiation potential of MSC, with periostin (POSTN), ﬁbroblast
growth factor 1 (FGF1), insulin-like growth factor binding protein 7
(IGFBP7) and transmembrane glycoprotein NMB (GPNMB) as the
most up-regulated proteins.
Pathway analysis revealed that vesicle-related proteins are highly
prominent in MSC, consistent with other ﬁndings reporting the central
role of vesicle production in these cells [9,25]. BothMSC populations are
enriched with almost identical terms (KEGG pathway) (Fig. 2E, Fig. S3,
DataSet S1), among which were complement and coagulation cascade,
osteoclast differentiation, ErbB, Hif-1, and TLR signaling. Notably, pro-
lactin, sphingolipid, FoxO, VEGF and neurotrophin signalingwere signif-
icantly up-regulated in MSC (Fig. 2E). This last ﬁnding is particularly
relevant as BM-MSC have been shown to have neurotrophic potential
and support synapse formation and neurological recovery [26]. Further-
more, neurotrophins regulating neurogenesis were shown recently to
induce transdifferentiation of human BM-MSC into neurons [27].
3.2.5. MSC subtype comparison
Comparing the two MSC populations revealed that proteins involved
in organ and system development were more enriched in BM-MSC,
whereas proteins involved in cellular component movement, cell migra-
tion, regulation of phosphorylation, extracellular matrix organization
and cell communication more in ESC-MSC. The most distinct differences
were found for signaling pathways, with cytokine-cytokine receptor
interaction, Jak-Stat, neurotrophin and PPAR signaling enriched in ESC-
MSC (Fig. S3C). In general, proteins differentially expressed between
both MSC populations are associated with terms related to extracellular
matrix (ECM) and vesicle proteins. The ECM protein matrix
metallopeptidase (MMP) 2 is the strongest up-regulated protein in BM-
MSC,whereasMMP1 is the dominantMMP in ESC-MSC.MMPs are impli-
cated in homing [28], one of the characteristic features of MSC. Notably,
ICAM5, the protein overexpressed strongest in ESC-MSCwhen compared
to BM-MSC, is a neuron-speciﬁc adhesion molecule which stimulates
neuron excitability after cleavage by MMPs [29]. Soluble ICAM5 has
been shown to strongly induce neurite outgrowth and suppress immune
response [30] and although it has not been associatedwithMSC function-
ality, it might be involved in the neurogenic potential of MSC.
3.3. Comparison of SOMAscan data with LC-MS/MS and RNA sequencing
In total, 599 out of the 1095 proteins targeted by the assaywere also
measured by nano LC-MS/MS or RNA sequencing, which corresponds to
an overlap of approximately 55%. Furthermore, 408 proteins were com-
monly quantiﬁed in all three datasets allowing for analytical platforms
comparison (Fig. S4A, top16 in Fig. S6). It is worth noting that the
SOMAscan-quantiﬁed proteins that were not detected by nano LC-MS/
MS or RNA sequencing were low abundant signaling molecules such
as cytokines, chemokines and interleukins. Due to this limitedmeasure-
ment overlap between platforms, the validation of the SOMAscan re-
sults is rendered difﬁcult, as only 36% of the SDE proteins in SOMA
were conﬁrmed by either PROT, RNA or both (Fig. S4B). However,
when considering the 408 proteins measured by all techniques, 60% of
the SOMA results were validated (Fig. 3A), which is comparable to re-
sults obtainedwhen comparing PROT to RNA data [6], however the cor-
relation of expression difference direction is not as substantial as that
observed for the latter two techniques (Fig. S4C). Indeed, MSC (both
subtypes) to ESC log2 ratio correlations ranked as follows from best to-E), ESC-MSC vs ESC (EM-E) and BM-MSC vs ESC-MSC (BM-EM). The total number of
ported in each panel. (B) Venn diagram of SDEs per comparisons (BM-E, EM-E, BM-EM).
otting the percentage of variance per component and reporting 2D plots of the ﬁrst 3. (E)
), and KEGG pathways for up-regulated proteins in MSC (red) and in ESC (blue). MSC vs
ﬁcant enriched terms per cell type sorted by the mean of –log10p values.
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Fig. 4. CD markers. (A) Numbers of CD markers measured by SOMA, RNA and PROT. (B) Differentially expressed CD markers found by SOMA and validated by at least one alternative
technique (RNA, PROT).
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PROT (BM-E: 0.6 and EM-E: 0.54) and SOMA to RNA (BM-MSC vs ESC:
0.5 and ESC-MSC vs ESC: 0.49) (Fig. 3B). These results may be partially
due to the limited overlap of identiﬁcations, but a major analytical dif-
ference in the characteristics of the techniques is likely to also play a
central role: The underlying principle of the aptamer-based assay is epi-
tope recognition, thus relative quantitation may reﬂect changes in pro-
tein abundance or epitope accessibility, which may occur for example
through occlusion by post-translational modiﬁcation or protein-protein
interaction. In fact, enrichment analysis of proteins differentially
expressed between subsets by SOMA supports this hypothesis. Among
the 408 commonly measured proteins, the SOMA SDEs that were not
validated by any of the other two techniques (top16 in Fig. S7) were
found to be highly enriched for terms related to post-translationalmod-
iﬁcation (“acetylation” FDR 1 × 10−16, “phosphorylation” FDR
1 × 10−7), reﬂecting the nature of SOMAscan as an assay monitoring
epitope availability rather than protein concentration (Fig. 3C).3.4. Enrichment analysis considering all three techniques: SOMAscan, LC-
MS/MS and RNA sequencing
Enrichment analysis was performed for all three data sets and inte-
grated (Fig. S5, DataSet S1). It is apparent that despite the limited over-
lap between SOMAscan and the other two techniques the targeted
proteomics platform picks up very similar functions and pathways asFig. 3. Differential expression analysis for SOMA, RNA-seq and LC-MS/MS. (A) Cross validation
differentially expressed proteins (SDEs) (FDR b 0.05) found by the three techniques (RNA, PRO
BM-MSC N ESC-MSC, BM-MSC b ESC-MSC. Venn diagrams report only proteins that have been
the three large scale data sets (RNA, PROT, SOMA). (C) Enrichment analysis on SwissProt k
the 408 common proteins measured by all three techniques, SDEs found by SOMA were sub
SOMA (blue).shotgun proteomics and RNA sequencing (Fig. S5A). Top enriched bio-
logical processes in MSC include response to wound healing, regulation
of cell proliferation, vesicle-mediated transport and cell adhesion. With
respect to regeneration, proteins related to developmental processes,
blood vessel and skeletal system development were enriched in both
MSC populations and were found by all three omics techniques. Top
KEGG pathways in MSC include for instance focal adhesion, PI3K-Akt,
neurotrophin, and ErbB signaling.
ESCs are exceptional in terms of cellular content and nucleus to cyto-
sol ratio. They are highly enriched in nuclear proteins, which are in-
volved in cell cycle, RNA processing, DNA repair and transcription. Due
to the under-representation of those protein classes in the SOMAscan
assay, the characteristic nature of this cell type is not well reﬂected
when compared to LC-MS/MS and RNA-seq (Fig. S5B). However, the
targeted proteomics approachmakes signalingmolecules and receptors
accessible also in ESC (Fig. S5B, C).3.5. Phenotyping of ESC andMSC by surfacemarkers: new insights provided
by SOMAscan
With MSC being the most prominent candidate in stem cell-based
therapy, a comprehensive characterization of surface markers becomes
crucial. Previously, we presented a list of 137 CDmarkers of MSC, which
were proﬁled by a combination of RNA-seq and LC-MS/MS [6]. Remark-
ably, the SOMAscan assay alone covers 144 CD markers and whenof SOMA by RNA-seq (RNA) and nano LC-MS/MS (PROT). Comparison between signiﬁcant
T, SOMA) for all six cases: BM-MSC N ESC, BM-MSC b ESC, ESC-MSC N ESC, ESC-MSC b ESC,
measured by all three techniques (RNA, PROT, SOMA). (B) Pearson correlation between
eywords for up-regulated proteins in MSC for BM-E and EM-E comparisons. Based on
set into proteins cross-validated by RNA and PROT (red) and proteins found solely by
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95A.M. Billing et al. / Journal of Proteomics 150 (2017) 86–97combining it with the other two techniques, 221 CDmarkers weremea-
sured, with 85 uniquely added by SOMA (Fig. 4A, Table S2). Considering
SOMA alone, signiﬁcantly up-regulated in MSC when compared to ESC
were 36 common CD markers with 9 speciﬁc for BM-MSC and 7 for
ESC-MSC. Signiﬁcantly up-regulated in ESC when compared to MSC
were 61 common CD markers with 4 speciﬁc when compared to BM-
MSC and 5 speciﬁc when compared to ESC-MSC. Both MSC populations
were differentiated by 9 CD markers (MPL, CD80, F3, DDR1, CD36,
TNFRSF12A, IL10RB, MST1R, LIFR) enriched in ESC-MSC and 3 CD
markers enriched in BM-MSC (BST1, TEK, EMR2). Some differentially
expressed CD markers were validated by at least one other technique
(RNA, PROT) (Fig. 4B). CD markers cross validated by all three tech-
niques can be considered a high conﬁdence set and include: for ESC:
Kit (CD117), IGF1R (CD221), BCAM (CD239), BMPR1A (CD292), CDH1
(CD324), FGFR1 (CD331), and ERBB2 (CD340); for MSC: ITGAV
(CD51), ICAM1 (CD54), PLAUR (CD87), ENG (CD105), TNFRSF1A
(CD120a), IL6ST (CD130), PDGFRB (CD140b), ALCAM (CD166), IGF2R
(CD222), TNFRSF10D (CD264), MRC2 (CD280), NRP1 (CD304) and
JAG1 (CD339) (Fig. 5A).
Some of these high conﬁdence CD markers are well established ESC
(CD117, CD324) and MSC markers (CD51, CD54, CD105 and CD166),
while others are novel and potentially offer new avenues for cell type
deﬁnition.
It is believed that surface receptors are involved in homing,
immunomodulation and regeneration support of MSC. Among the
high conﬁdence MSC marker, Notch ligand Jagged-1 (JAG1, CD339),
has recently been shown to be crucial for the MSC-induced expansion
of TREG cells [31], further validating the data set beyondmore canonical
molecules.
High conﬁdence CD marker found for BM-MSC was VCAM1
(CD106), for ESC-MSC LIFR (CD118). In concordance with others,
CD106 was found to be low on ESC-MSC in comparison to BM-MSC.
Its decrease correlates with diminished lineage differentiation, noted
to be less efﬁcient in ESC-MSC than BM-MSC when considering adipo-
genesis and chondrogenesis [32].
3.6. New ﬁndings based on uniquely quantiﬁed proteins by SOMAscan
SOMAscan as a targeted proteomics platform is very sensitive and
can accurately quantify low expressed proteins, overcoming
masking effects by high abundant complex backgrounds. A total of
496 proteins were uniquely measured by SOMA when compared to
RNA and PROT (Fig. S4A) with 265 proteins signiﬁcantly up-regulat-
ed in ESC (vs MSC, BM-MSC: 18, ESC-MSC: 23, both MSC: 224) and
131 proteins up-regulated in MSC (vs ESC, BM-MSC: 16, ESC-MSC:
12, both MSC: 103) (top 16 in Fig. S8). Among up-regulated proteins
in ESC in comparison to both MSC were for instance chemokines
(CCL3, CCL4L1, CCL13, CCL17, CCL20, CCL21, CCL22, CCL23, CCL24,
CCL25, CCL27, CXCL3, CXCL10, CXCL13), interleukins (IL2, IL4,
IL12A, IL17B, IL20, IL24, IL25, IL34), interleukin receptors (IL5RA,
IL6R, IL10RB, IL12RB1, IL15RA, IL22RA, IL27RA), tumor necrosis fac-
tors (TNF, TNFSF8, TNFSF14, TNFSF15) and hormones (e.g. parathy-
roid hormone, pancreatic polypeptide, peptide YY, erythropoietin).
Among up-regulated proteins in MSC in comparison to ESC were
chemokines (CCL7, CCL14, CCL19, CCL3L1), interleukins (IL3, IL19),
interleukin receptors (IL2G, IL12RB2, IL23R), interferons (IFNG,
IFNA2), and tumor necrosis factors (TNFSF11). Among the 85 CD
markers uniquely measured by SOMA, 17 were up-regulated in
MSC (BM and EM) and 40 in ESC (Fig. 5B). Signiﬁcantly up-regulated
in ESC-MSCwhen compared to ESC and BM-MSCwere proteins relat-
ed to e.g. axon guidance (ICAM5, EPHA3), immune response (IL7,
IL12B) and ECM composition (ADAMTS15, SPARCL1). WhenFig. 5. Selection of signiﬁcant up-regulated proteins inMSC and ESC. (A) CDmarkers for MSC an
interleukins and interleukin receptors for MSC and ESC measured uniquely in SOMA.comparing to the most comprehensive proteomics datasets available
on MSC including an antibody-based array of the secretome [33–35],
539 new proteins were measured by SOMA, 118 among those being
signiﬁcantly enriched in MSC. Including our LC-MS/MS dataset in
this comparison, 466 proteins were uniquely measured, 97 of
which being MSC speciﬁc.4. Discussion
Performing a fair comparison between proteomics technologies is
inherently difﬁcult as detection paradigm and overall analytical ap-
proaches differ signiﬁcantly. Although comparing targeted and
untargeted approaches is bound to be biased, evaluating quantiﬁcation
repeatability across various platforms may provide useful insights into
cross validation strategies. Keeping that in mind, we report here on
the complementarity of the aptamer-based SOMAscan assay to other
analytical platforms, namely mass spectrometry and RNA sequencing,
in the context of mesenchymal stem cell sourcing characterization.
The use of a cellular extract as amodel system to compare across the an-
alytical platforms allowed us to overcome the classical challenge associ-
ated with dynamic range in the analysis of bio ﬂuids by mass
spectrometry-based approaches. This comes, however, at the cost of ap-
plying SOMAscan to a sample type it is not designed to address. Due to
its targeted nature and high sensitivity, the assay nonetheless allows
quantiﬁcation of targets typically at or below limits of detections of
standard platforms. Indeed, dynamic range distributions showed
SOMAscan to more comprehensively cover the abundance range of ref-
erence sets derived from deep transcriptomic analysis from the litera-
ture, whereas RNA and PROT gave substantially less congruency.
Measurement repeatability assessment revealed comparable distribu-
tions between platforms with an expected advantage to the targeted
approach. Although a comparison between the SOMAscan assay and a
targeted mass spectrometry approach would be more appropriate, es-
tablishing targeted MS-assays (using multiple reaction monitoring)
covering all SOMAscan targets (1129) was beyond the scope of this
work.
Overall, the complementarity of platforms is highlighted by the bal-
ance between sensitivity and comprehensiveness and further conﬁrms
the beneﬁts of combining approaches for in-depth systems biology.
SOMAscan results are largely in accordance with the proteome and
transcriptome measurements, based on the 408 proteins commonly
quantiﬁed with all three techniques. Correlation with RNA sequencing
reached 0.5, which is within the expected range between proteome
and transcriptome, while comparing to MS-based proteome analysis
the correlation score increased to 0.58. Overall, 60% of differentially
expressed proteins reported by the SOMAscan assay and quantiﬁed by
all three techniques were cross validated by either RNA sequencing,
MS-based proteomics or both reﬂecting consistent changes in gene
product abundance measured across all techniques. The remaining
40% of differentially expressed proteins which were not cross validated
by the other techniques (LC-MS/MS, RNA sequencing) were enriched in
terms related to posttranslationalmodiﬁcation, suggesting that changes
of epitope accessibility, for example by post-translational modiﬁcation
rather than variations in protein abundance, may be at the root of
those divergences. Although the overlap of 408 proteins, which were
measured across all three techniques, remains modest, enrichment
and pathway analysis on the complete SOMAscan data set proved that
the targeted proteomics platform gives similar results toMS-based pro-
teomics and RNA sequencing with the notable exception of ESC - likely
due to their high content in nuclear proteins, underrepresented in the
assay. The proteomic equivalence between the two MSC subtypes hasd ESC validated by all three techniques (RNA, PROT, SOMA). (B) CDmarkers, chemokines,
96 A.M. Billing et al. / Journal of Proteomics 150 (2017) 86–97been conﬁrmed by the SOMAscan assay, further validating ESC-MSC as a
possible substitution to BM-MSC.
These ﬁndings highlight the capabilities andmerits of the SOMAscan
assay which proves complementary to other omics approaches and
allows, due to its combined sensitivity and selectivity, to overcome dy-
namic range limitations, making it particularly adapted to investigation
of signaling pathways.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jprot.2016.08.023.
Author contributions
JG, AR and KS directed the study. AMB designed the experiments.
AMB and SSD carried out the experiments. AMB, HBH and AB analyzed
proteomics data and performed bioinformatics analysis. HBH and NG
measured samples bymass spectrometry. SH andPKperformedRNA se-
quencing data processing. AMB, SH, PK and NY performed statistics.
AMB, RJC, HBH and AMB created ﬁgures. AMB, HBH and JG drafted the
manuscript.
Conﬂict of interest
The authors declare no competing ﬁnancial interest.
Transparency document
The Transparency document associated with this article can be
found, in online version.
Acknowledgements
J.G. and the Proteomics Core atWCMC-Q are supported by “Biomed-
ical Research Program” funds atWeill CornellMedical College in Qatar, a
program funded by Qatar Foundation. This work was supported by a
grant from Qatar National Research Fund's National Priority Research
Program (4-1267-1-194). The statementsmade herein are solely the re-
sponsibility of the authors.
References
[1] L. Gold, J.J. Walker, S.K. Wilcox, S. Williams, Advances in human proteomics at high
scalewith the SOMAscan proteomics platform, New Biotechnol. 29 (2012) 543–549,
http://dx.doi.org/10.1016/j.nbt.2011.11.016.
[2] J.C. Rohloff, A.D. Gelinas, T.C. Jarvis, U.A. Ochsner, D.J. Schneider, L. Gold, N. Janjic,
Nucleic acid ligands with protein-like side chains: modiﬁed aptamers and their
use as diagnostic and therapeutic agents, Mol. Ther.—Nucleic Acids. 3 (2014),
e201 http://dx.doi.org/10.1038/mtna.2014.49.
[3] S. Surinova, R. Schiess, R. Hüttenhain, F. Cerciello, B.Wollscheid, R. Aebersold, On the
development of plasma protein biomarkers, J. Proteome Res. 10 (2011) 5–16,
http://dx.doi.org/10.1021/pr1008515.
[4] M.R. Mehan, D. Ayers, D. Thirstrup, W. Xiong, R.M. Ostroff, E.N. Brody, J.J. Walker, L.
Gold, T.C. Jarvis, N. Janjic, G.S. Baird, S.K. Wilcox, Protein signature of lung cancer tis-
sues, PLoS One 7 (2012), e35157 http://dx.doi.org/10.1371/journal.pone.0035157.
[5] J. Webber, T.C. Stone, E. Katilius, B.C. Smith, B. Gordon, M.D. Mason, Z. Tabi, I.A.
Brewis, A. Clayton, Proteomics analysis of cancer exosomes using a novel modiﬁed
aptamer-based array (SOMAscanTM) platform, Mol. Cell. Proteomics 13 (2014)
1050–1064, http://dx.doi.org/10.1074/mcp.M113.032136.
[6] A.M. Billing, H. Ben Hamidane, S.S. Dib, R.J. Cotton, A.M. Bhagwat, P. Kumar, S. Hayat,
N.A. Yousri, N. Goswami, K. Suhre, A. Raﬁi, J. Graumann, Comprehensive
transcriptomic and proteomic characterization of human mesenchymal stem cells
reveals source speciﬁc cellular markers, Sci. Rep. 6 (2016) 21507, http://dx.doi.
org/10.1038/srep21507.
[7] A.J. Friedenstein, K.V. Petrakova, A.I. Kurolesova, G.P. Frolova, Heterotopic of bone
marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues, Trans-
plantation 6 (1968) 230–247.
[8] M.F. Pittenger, A.M. Mackay, S.C. Beck, R.K. Jaiswal, R. Douglas, J.D. Mosca, M.A.
Moorman, D.W. Simonetti, S. Craig, D.R. Marshak, Multilineage potential of adult
human mesenchymal stem cells, Science 284 (1999) 143–147.
[9] S. Rani, A.E. Ryan, M.D. Grifﬁn, T. Ritter, Mesenchymal stem cell-derived extracellu-
lar vesicles: toward cell-free therapeutic applications, Mol. Ther. 23 (2015)
812–823, http://dx.doi.org/10.1038/mt.2015.44.
[10] C.M. Raynaud, N. Halabi, D.A. Elliott, J. Pasquier, A.G. Elefanty, E.G. Stanley, A. Raﬁi,
Human embryonic stem cell derived mesenchymal progenitors express cardiacmarkers but do not form contractile cardiomyocytes, PLoS One 8 (2013), e54524
http://dx.doi.org/10.1371/journal.pone.0054524.
[11] L. Gold, D. Ayers, J. Bertino, C. Bock, A. Bock, E.N. Brody, J. Carter, A.B. Dalby, B.E. Eaton, T.
Fitzwater, D. Flather, A. Forbes, T. Foreman, C. Fowler, B. Gawande,M. Goss, M. Gunn, S.
Gupta, D. Halladay, J. Heil, J. Heilig, B. Hicke, G. Husar, N. Janjic, T. Jarvis, S. Jennings, E.
Katilius, T.R. Keeney, N. Kim, T.H. Koch, S. Kraemer, L. Kroiss, N. Le, D. Levine, W.
Lindsey, B. Lollo, W. Mayﬁeld, M. Mehan, R. Mehler, S.K. Nelson, M. Nelson, D.
Nieuwlandt, M. Nikrad, U. Ochsner, R.M. Ostroff, M. Otis, T. Parker, S. Pietrasiewicz,
D.I. Resnicow, J. Rohloff, G. Sanders, S. Sattin, D. Schneider, B. Singer, M. Stanton, A.
Sterkel, A. Stewart, S. Stratford, J.D. Vaught, M. Vrkljan, J.J. Walker, M. Watrobka, S.
Waugh, A. Weiss, S.K. Wilcox, A. Wolfson, S.K. Wolk, C. Zhang, D. Zichi, Aptamer-
based multiplexed proteomic technology for biomarker discovery, PLoS ONE 5
(2010), e15004 http://dx.doi.org/10.1371/journal.pone.0015004.
[12] J. Rappsilber, Y. Ishihama, M. Mann, Stop and go extraction tips for matrix-assisted
laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in
proteomics, Anal. Chem. 75 (2003) 663–670.
[13] A.R. Liberski, M.N. Al-Noubi, Z.H. Rahman, N.M. Halabi, S.S. Dib, R. Al-Mismar, A.M.
Billing, R. Krishnankutty, F.S. Ahmad, C.M. Raynaud, A. Raﬁi, K. Engholm-Keller, J.
Graumann, Adaptation of a commonly used, chemically deﬁned medium
for human embryonic stem cells to stable isotope labeling with amino acids in cell
culture, J. Proteome Res. 12 (2013) 3233–3245, http://dx.doi.org/10.1021/
pr400099j.
[14] J. Cox, M. Mann, MaxQuant enables high peptide identiﬁcation rates, individualized
p.p.b.-range mass accuracies and proteome-wide protein quantiﬁcation, Nat.
Biotechnol. 26 (2008) 1367–1372, http://dx.doi.org/10.1038/nbt.1511.
[15] C. Trapnell, A. Roberts, L. Goff, G. Pertea, D. Kim, D.R. Kelley, H. Pimentel, S.L.
Salzberg, J.L. Rinn, L. Pachter, Differential gene and transcript expression analysis
of RNA-seq experiments with TopHat and cufﬂinks, Nat. Protoc. 7 (2012)
562–578, http://dx.doi.org/10.1038/nprot.2012.016.
[16] H. Li, B. Handsaker, A. Wysoker, T. Fennell, J. Ruan, N. Homer, G. Marth, G. Abecasis,
R. Durbin, 1000 genome project data processing subgroup, the sequence alignment/
map format and SAMtools, Bioinforma. Oxf. Engl. 25 (2009) 2078–2079, http://dx.
doi.org/10.1093/bioinformatics/btp352.
[17] M.E. Ritchie, B. Phipson, D. Wu, Y. Hu, C.W. Law, W. Shi, G.K. Smyth, limma powers
differential expression analyses for RNA-sequencing andmicroarray studies, Nucleic
Acids Res. 43 (2015), e47 http://dx.doi.org/10.1093/nar/gkv007.
[18] R. Core Team, R: A Language and Environment for Statistical Computing, R Founda-
tion for Statistical Computing, Vienna, Austria, 2015http://www.R-project.org.
[19] M.P. Schwartz, Z. Hou, N.E. Propson, J. Zhang, C.J. Engstrom, V.S. Costa, P. Jiang, B.K.
Nguyen, J.M. Bolin, W. Daly, Y. Wang, R. Stewart, C.D. Page, W.L. Murphy, J.A.
Thomson, Human pluripotent stem cell-derived neural constructs for predicting
neural toxicity, Proc. Natl. Acad. Sci. 112 (2015) 12516–12521, http://dx.doi.org/
10.1073/pnas.1516645112.
[20] B. Roson-Burgo, F. Sanchez-Guijo, C.D. Cañizo, J.D.L. Rivas, Transcriptomic portrait of
human mesenchymal stromal/stem cells isolated from bone marrow and placenta,
BMC Genomics 15 (2014) 910, http://dx.doi.org/10.1186/1471-2164-15-910.
[21] H. Mi, A. Muruganujan, J.T. Casagrande, P.D. Thomas, Large-scale gene function anal-
ysis with the PANTHER classiﬁcation system, Nat. Protoc. 8 (2013) 1551–1566,
http://dx.doi.org/10.1038/nprot.2013.092.
[22] F. Husson, J. Josse, S. Le, J, Mazet, FactoMineR, Multivariate Exploratory Data Analysis
and Data Mining, 2015 http://cran.r-project.org/web/packages/FactoMineR/index.
html accessed February 8, 2015.
[23] S. Ghaemmaghami, W.-K. Huh, K. Bower, R.W. Howson, A. Belle, N. Dephoure, E.K.
O'Shea, J.S. Weissman, Global analysis of protein expression in yeast, Nature 425
(2003) 737–741, http://dx.doi.org/10.1038/nature02046.
[24] V. Nanjappa, J.K. Thomas, A. Marimuthu, B. Muthusamy, A. Radhakrishnan, R.
Sharma, A.A. Khan, L. Balakrishnan, N.A. Sahasrabuddhe, S. Kumar, B.N. Jhaveri,
K.V. Sheth, R.K. Khatana, P.G. Shaw, S.M. Srikanth, P.P. Mathur, S. Shankar, D.
Nagaraja, R. Christopher, S. Mathivanan, R. Raju, R. Sirdeshmukh, A. Chatterjee, R.J.
Simpson, H.C. Harsha, A. Pandey, T.S.K. Prasad, Plasma proteome database as a re-
source for proteomics research: 2014 update, Nucleic Acids Res. 42 (2014)
D959–D965, http://dx.doi.org/10.1093/nar/gkt1251.
[25] T. Katsuda, N. Kosaka, F. Takeshita, T. Ochiya, The therapeutic potential ofmesenchy-
mal stem cell-derived extracellular vesicles, Proteomics 13 (2013) 1637–1653,
http://dx.doi.org/10.1002/pmic.201200373.
[26] M. Mauri, D. Lentini, M. Gravati, D. Foudah, G. Biella, B. Costa, M. Toselli, M. Parenti,
S. Coco, Mesenchymal stem cells enhance GABAergic transmission in co-cultured
hippocampal neurons, Mol. Cell. Neurosci. 49 (2012) 395–405, http://dx.doi.org/
10.1016/j.mcn.2012.02.004.
[27] H.-L. Tsai, W.-P. Deng, W.-F.T. Lai, W.-T. Chiu, C.-B. Yang, Y.-H. Tsai, S.-M. Hwang, P.F.
Renshaw, Wnts enhance neurotrophin-induced neuronal differentiation in adult
bone-marrow-derivedmesenchymal stem cells via canonical and noncanonical signal-
ing pathways, PLoS One 9 (2014), e104937 http://dx.doi.org/10.1371/journal.pone.
0104937.
[28] I.A.W. Ho, K.Y.W. Chan, W.-H. Ng, C.M. Guo, K.M. Hui, P. Cheang, P.Y.P. Lam, Matrix
metalloproteinase 1 is necessary for the migration of human bone marrow-derived
mesenchymal stem cells toward human glioma, Stem Cells Dayt. Ohio. 27 (2009)
1366–1375, http://dx.doi.org/10.1002/stem.50.
[29] M. Niedringhaus, X. Chen, R. Dzakpasu, K. Conant, MMPs and soluble ICAM-5 in-
crease neuronal excitability within in vitro networks of hippocampal neurons,
PLoS One 7 (2012), e42631 http://dx.doi.org/10.1371/journal.pone.0042631.
[30] C.G. Gahmberg, L. Ning, S. Paetau, ICAM-5: a neuronal dendritic adhesion mol-
ecule involved in immune and neuronal functions, Adv. Neurobiol. 8 (2014)
117–132.
[31] E.F. Cahill, L.M. Tobin, F. Carty, B.P. Mahon, K. English, Jagged-1 is required for the ex-
pansion of CD4+ CD25+ FoxP3+ regulatory T cells and tolerogenic dendritic cells
97A.M. Billing et al. / Journal of Proteomics 150 (2017) 86–97by murine mesenchymal stromal cells, Stem Cell Res. Ther. 6 (2015) http://dx.doi.
org/10.1186/s13287-015-0021-5.
[32] P.T. Brown, M.W. Squire, W.-J. Li, Characterization and evaluation of mesenchymal
stem cells derived from human embryonic stem cells and bone marrow, Cell Tissue
Res. 1–16 (2014) http://dx.doi.org/10.1007/s00441-014-1926-5.
[33] R.J. Holley, G. Tai, A.J.K.Williamson, S. Taylor, S.A. Cain, S.M. Richardson, C.L.R. Merry,
A.D. Whetton, C.M. Kielty, A.E. Canﬁeld, Comparative quantiﬁcation of the
surfaceome of human multipotent mesenchymal progenitor cells, Stem Cell Rep. 4
(2015) 473–488, http://dx.doi.org/10.1016/j.stemcr.2015.01.007.[34] S.T. Mindaye, M. Ra, J.L. Lo Surdo, S.R. Bauer, M.A. Alterman, Global proteomic signa-
ture of undifferentiated human bone marrow stromal cells: evidence for donor-to-
donor proteome heterogeneity, Stem Cell Res. 11 (2013) 793–805, http://dx.doi.
org/10.1016/j.scr.2013.05.006.
[35] S.K. Sze, D.P.V. de Kleijn, R.C. Lai, E.K.W. Tan, H. Zhao, K.S. Yeo, T.Y. Low, Q. Lian, C.N.
Lee, W. Mitchell, R.M. El Oakley, S.-K. Lim, Elucidating the secretion proteome of
human embryonic stem cell-derived mesenchymal stem cells, Mol. Cell. Proteomics
MCP. 6 (2007) 1680–1689, http://dx.doi.org/10.1074/mcp.M600393-MCP200.
